Company Enabling Next-Generation Vaccines using Nanopatch™ Platform
Brisbane, Australia – 18 March 2013 – Vaxxas, a biotechnology company commercializing a novel vaccine-delivery platform that activates immunological cells immediately below the surface of the skin, announced today it has received the BioSpectrum Asia-Pacific Emerging Company of the Year Award. The award recognizes Vaxxas for the potential of its needle-free Nanopatch™ platform to enhance delivery efficiency and improve effectiveness of a wide range of vaccines.
"We thank BioSpectrum Asia-Pacific for recognizing Vaxxas and the tremendous potential of the Nanopatch platform," said David Hoey, Chief Executive Officer of Vaxxas. "Our team is working hard to advance the core science as we engage industry partners in preparation for our first clinical demonstrations.”
The Company announced a research collaboration with Merck in October 2012 to explore use of the Nanopatch with certain vaccines. Later that same month, the Company was awarded the 2012 Janssen AusBiotech Emerging Company of the Year.
Vaxxas was founded in August 2011 with the completion of a $15M Series A equity financing. In late 2012 the company opened a commercialization office in Cambridge, Massachusetts to expand access to global pharmaceutical partners and complement the Company’s research and development operations based in Queensland, Australia.
Notes to Editors
Vaxxas is a privately-held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary Nanopatch™ technology platform. Vaxxas’ Nanopatch contains an ultra-high density array of projections – invisible to the naked human eye – that are dry-coated with vaccine. Application of the Nanopatch to the skin is pain free and rapidly delivers the vaccine to the abundant immune cell population immediately below the skin surface. In a wide range of preclinical studies Nanopatch delivery of vaccine achieves equivalent protective immunity as the needle and syringe – but with only 1/100th of the dose. It has also been shown that Vaxxas’ proprietary dry-coating technology can eliminate the need for vaccine refrigeration during storage and transportation – removing the resource burden of maintaining the “cold chain.” Leveraging both the potent immunogenic response and thermostability, Vaxxas is applying its technology to improve the performance of vaccines, with initial applications targeting infectious disease and oncology. The company recently announced its first collaboration with Merck.
Vaxxas’ Nanopatch technology originated from Professor Mark Kendall's research group at the Australian Institute of Bioengineering and Nanotechnology at The University of Queensland, the Australian university where some of the groundbreaking immunological work on human papilloma virus vaccines was performed. The University of Queensland’s main commercialization company, UniQuest, led the initial commercialization of the Nanopatch technology prior to the creation of Vaxxas in 2011. Vaxxas is backed by a strong group of venture investors including OneVentures, Brandon Capital, Healthcare Ventures, and the Medical Research Commercialisation Fund.
The company is initially focused on partnering with leading vaccine companies who are seeking a needle-free, differentiated, high performance, cost effective and safe vaccine delivery platform. For more information, please visit www.vaxxas.com
Issued for and on behalf of Vaxxas,